Clinical Trial Protocol
Iranian Registry of Clinical Trials

16 Sep 2026

Vaccination of diffuse B cell lymphoma patients by use of tumor antigens and autologous dendritic cells complex

Protocol summary

Summary

The Purpose of this study is to determine the effect of dendritic cells and tumor antigen complex capability in preventing tumor development. 10 lymphoma subjects will be randomly divided to two equal groups. After antigen priming, one group will receive a median of 6.5 × 1000000 dendritic cells which are subcutaneously injected close to inguinal lymph nodes, twice a day. TCD4 and tumor size will be measured one week after intervention.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT138712071715N1**
Registration date: **2009-05-31, 1388/03/10**
Registration timing: **prospective**

Last update:
Update count: **0**

Registration date

2009-05-31, 1388/03/10

Registrant information

Name
Saeid Abedian
Name of organization / entity
Mazandaran University of Medical Sciences
Country
Iran (Islamic Republic of)
Phone
+98 335430810151
Email address
sabedian@mazums.ac.ir

Recruitment status

Recruitment complete

Funding source

Mazandaran University of Medical Sciences and Health Services

Expected recruitment start date

2009-06-22, 1388/04/01

Expected recruitment end date

2011-11-22, 1390/09/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Vaccination of diffuse B cell lymphoma patients by use of tumor antigens and autologous dendritic cells complex

Public title

Vaccination of cancer patients for preventing cancer development

Purpose

Prevention

Inclusion/Exclusion criteria

Inclusion criteria: Presence of diffuse b cell lymphoma
Exclusion criteria: Presence o any other kind of cancer except for lymphoma

Age

From **40 years** old to **60 years** old

Gender

Both

Phase

1

Groups that have been masked

No information

Sample size

Target sample size: **10**

Randomization (investigator's opinion)

Randomized

Randomization description

Blinding (investigator's opinion)

Not blinded
Blinding description
Placebo
Not used
Assignment
Parallel
Other design features

Secondary Ids

1

Registry name
Lymphoma
Secondary trial Id
Registration date
2009-04-05, 1388/01/16

Ethics committees

1

Ethics committee
Name of ethics committee
Mazandaran University of Medical Sciences and Health Services
Street address
Mazandaran University of Medical Sciences, Imam sqare,
City
Sari
Postal code
Approval date
2009-03-03, 1387/12/13
Ethics committee reference number
116-87

Health conditions studied

1

Description of health condition studied
Lymphoma
ICD-10 code
C85.1
ICD-10 code description
B-cell lymphoma, unspecified

Primary outcomes

1

Description
The number of TCD4
Timepoint
one week after injection
Method of measurement
Flocytometry

2

Description
The number of TCD8
Timepoint
one week after injection
Method of measurement
Flocytometry

Secondary outcomes

1

Description
Interleukin 2
Timepoint
7 to 14 days after injection
Method of measurement
eliza

2

Description
Interleukin 4
Timepoint
7 to 14 days after injection
Method of measurement
ELIZA method

3

Description
Interleukin 10
Timepoint
7 to 14 days after injection
Method of measurement
ELIZA method

4

Description
Interleukin 17
Timepoint
7 to 14 days after injection
Method of measurement
ELIZA method

Intervention groups

1

Description
After antigen priming, subcutaneous injection of median of 6.5 × 1000000 (0.5 ml) dendritic cells, close to inguinal lymph nodes, twice a day
Category
empty

Recruitment centers

1

Recruitment center

Name of recruitment center
Imam Khomaini Hospital

Full name of responsible person
Saeid Abedian

Street address
Medecine collage, Mazandaran University of Medical Sciences

City
Sari

Sponsors / Funding sources

1

Sponsor

Name of organization / entity
Mazandaran University of Medical Sciences

Full name of responsible person
Saied Abedian

Street address
Medecine collage, Mazandaran University of medical Sciences

City
Sari

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?
Yes

Title of funding source
Mazandaran University of Medical Sciences

Proportion provided by this source
100

Public or private sector
empty

Domestic or foreign origin
empty

Category of foreign source of funding
empty

Country of origin

Type of organization providing the funding
empty

Person responsible for general inquiries

Contact

Name of organization / entity
Mazandaran University of Medical Sciences

Full name of responsible person
Motahareh Kheradmand

Position
Master of Science on Nursing.

Other areas of specialty/work

Street address
Moallem square,

City
Sari

Postal code
00981514817844718

Phone
+98 15132612458

Fax

Email
elhamkheradmand2003@yahoo.comkheradmand@mazums.ac.ir

Web page address

Person responsible for scientific inquiries

Contact

Name of organization / entity
Mazandaran University of Medical Sciences

Full name of responsible person
Saeid Abedian

Position
PhD in Immunology

Other areas of specialty/work

Street address
Medicine collage, Mazandaran University of Medical Sciences,

City
Sari

Postal code

Phone
+98 35 43249

Fax

Email
abedianlab@yahoo.co.ukabedianks@razi.tums.ac.irsabedian@mazums.ac.ir

Web page address

Person responsible for updating data

Contact

Name of organization / entity
Mazandaran University of Medical Sciences

Full name of responsible person
Saeid Abedian

Position
PhD in Immunology/Assistant Professor

Other areas of specialty/work

Street address
Medecine collage, Mazandaran university of Medical Sciences

City
Sari

Postal code

Phone
+98 15 1354 3249

Fax

Email
abedianlab@yahoo.co.ukabedianks@razi.tums.ac.irsabedian@mazums.ac.ir

Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)
empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty